Tularik Inc. (TLRK) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (193)	5/15/2002 10:56:14 AM
From: scaram(o)uche	Read Replies (1) of 598

Our second anti-cancer drug candidate, T607, is an analog of T67. The phase 2 dosing regimen has been selected, and we expect to begin phase 2 studies during the second quarter. Malignancies to be studied include hepatocellular carcinoma, non-Hodgkin’s lymphoma, gastric/esophageal cancer and ovarian cancer. Data from certain phase 1 trials with T607 will be available at the ASCO meeting. Our third anti-cancer drug candidate, T64, is an anti-metabolite. T64 is completing a phase 2 trial in 1st line non small-cell lung cancer (NSCLC). T64 demonstrated activity against NSCLC and melanoma in phase 2 trials, but did not demonstrate activity in other indications. We have recently initiated a phase 2 trial with T64 in 2nd line NSCLC, and we are in discussions with potential partners who may be interested in licensing this drug candidate. T611 is our oral drug candidate to prevent CMV disease in transplant patients. T611 is progressing through a phase 2 proof-of-concept trial in AIDS patients with CMV disease. We plan to initiate phase 2 studies in kidney transplant patients and in bone marrow transplant patients in the second half of 2002.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next